ClinicalTrials.gg
RecruitingNCT07492498Updated Oct 7, 2026

A Village Doctor-led Telehealth Supported Trial of Heart Failure Prevention in AF Patients: MIRACLE-AF 2 (Heart Failure Prevention)

An interventional study of Village-Doctor Led Integrated Care and Usual Care in Atrial Fibrillation and Heart Failure, sponsored by Jiangsu Taizhou People's Hospital. Recruiting at 3 sites in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Jiangsu Taizhou People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 7, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,356
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
33rd of 256
1,356 · median 235
Started
2026
with 47 others
No phase
200 of 377
100 open now
Primary completion
2033-12
later than 175 of 182 live
Registered
333rd of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 33rd largest by planned enrollment of the 256 interventional ones that give a count, is one of 48 that started in 2026, is one of 200 with no phase, reaches primary completion later than 175 of the 182 other live ones, and was the 333rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

156 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

This cluster randomized study aims to compare village doctor-led integrated care versus usual care to improve cardiovascular health, atrial fibrillation management, self-management adherence, and heart failure prevention among older rural patients with atrial fibrillation in China.The primary outcome at 12 months is the change in Life's Essential 8 cardiovascular health score from baseline (phase 1). The primary outcome at 36 months is a composite cardiovascular endpoint including cardiovascular death, ischemic or hemorrhagic stroke, hospitalization for worsening HF or acute coronary syndrome, and emergency department visits due to AF (phase 2) . The primary outcome at 48 months is new-incident heart-failure diagnosis (phase 3) .An extended observational follow-up, the new-incident heart-failure diagnosis observational follow-up study, will be conducted at Year 7 to evaluate long-term effects.

Read the detailed description

BACKGROUND Atrial fibrillation (AF) is common among older adults and is strongly associated with heart failure (HF), stroke, hospitalization, cardiovascular death, and all-cause mortality. AF and HF interact bidirectionally and may form a self-perpetuating cycle, particularly in older patients. Although the Atrial Fibrillation Better Care (ABC) pathway is recommended to improve the comprehensive management of AF, older adults with AF in rural China remain particularly vulnerable because of limited access to specialist care, inadequate HF screening and risk stratification, suboptimal implementation of guideline-recommended treatment, and insufficient continuity of follow-up. HF is one of the most common and clinically important complications of AF and is strongly associated with adverse prognosis. Therefore, AF management should extend beyond stroke prevention and incorporate earlier identification, prevention, and management of HF. China's rural primary healthcare system relies heavily on village doctors; however, village doctors often have limited clinical resources, standardized training, and access to specialist support, which may hinder the delivery of long-term integrated care for patients with AF who are at risk of developing HF. A telemedicine-supported, village-doctor-led integrated care model incorporating regular follow-up, medication review, cardiovascular risk monitoring, ABC pathway-based AF management, simplified exercise rehabilitation, timely specialist consultation, and structured patient education may therefore improve cardiovascular health and reduce the risk of incident HF in this population.

AIM OF THIS STUDY This cluster randomized study aims to compare village doctor-led integrated care versus usual care in improving cardiovascular health, guideline-based AF management, self-management adherence, clinical outcomes, and prevention of HF among older rural patients with AF in China.

DESIGN This study is a prospective, cluster randomized, open-label, parallel-group clinical trial conducted in rural China. The study aims to enroll older rural residents aged 65 to 80 years with documented AF and without a history or screening evidence of HF or asymptomatic left ventricular dysfunction at baseline. Village clinics in Jiangsu Province will be randomized in a 1:1 ratio to either the intervention group or the control group. Patients in the intervention group will receive telemedicine-supported, village doctor-led integrated care, including monthly follow-up, symptom assessment, vital-sign monitoring, medication adherence support, cardiovascular risk-factor management, ABC pathway-based AF care, simplified home-based exercise rehabilitation education, and remote cardiology consultation when needed. Village doctors will receive standardized training on stroke prevention and anticoagulation, symptom and rate/rhythm management, and management of cardiovascular risk factors and comorbidities. Patients in the control group will receive usual chronic disease management according to the National Basic Public Health Service requirements, including routine follow-up, general health education, medication documentation, and referral when clinically indicated.

03

Conditions studied

  • Atrial Fibrillation
  • Heart Failure
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. The village clinics need to be willing and able to provide integrated care to their patients with atrial fibrillation; 2. The village doctors from one village clinic serves all AF patients from 3-5 nearby villages; 3. The village doctors are trained to have a fundamental understanding of telemedicine; 4. Patients are eligible for participation if 1)they aged 65-80 years.

2)Availability of an confirming atrial fibrillation, or an official diagnosis certificate of atrial fibrillation issued by a specialist.

3)Receiving healthcare management from a primary medical institution near the place of residence.

4)Able to understand and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. A documented history of HF, or newly diagnosed HF according to the 2026 ESC Guidelines for the management of heart failure. HF will require current or prior typical symptoms and/or signs attributable to a structural and/or functional cardiac abnormality. Participants with \<50% will be classified as having heart failure with reduced ejection fraction (HFrEF). In participants with LVEF ≥50%, heart failure with preserved ejection fraction (HFpEF) will require objective evidence of cardiac structural and/or functional abnormalities consistent with left ventricular diastolic dysfunction or elevated filling pressures, supported by elevated natriuretic peptide levels. In participants with AF, supportive echocardiographic abnormalities will include left atrial volume index (LAVI) >40 mL/m², E/e' >15, pulmonary artery systolic pressure >35 mmHg, or tricuspid regurgitation velocity >2.8 m/s.
  2. Expected survival of less than 12 months.
  3. Severe renal insufficiency, defined as \<30 mL/min, or currently receiving dialysis treatment.
  4. Cardiac dysfunction caused by reversible secondary causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease.
  5. Indication for pacemaker implantation but without pacemaker placement.
  6. complicated by type II respiratory failure.
  7. Special populations, such as patients with mental illness.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,356 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    The intervention group will receive a village doctor-led integrated management program supported by telemedicine, guideline-based training, and a simplified exercise-based cardiac rehabilitation component, aiming to prevent incident heart failure in elderly rural patients with atrial fibrillation who have preserved cardiac function.

    Other: Village-Doctor Led Integrated Care

  • Active comparator
    Control Group

    Participants in this arm will receive usual chronic disease management according to the National Basic Public Health Service requirements.

    Other: Usual Care

Interventions

  • OtherVillage-Doctor Led Integrated Care

    1. Village doctor-led management. At least one follow-up contact per month will be completed at the clinic or at home, including symptom assessment, vital-sign monitoring, medication adherence management, cardiovascular risk-factor control and health guidance. 2. Telemedicine specialist support. When symptoms fluctuate, treatment adjustment is difficult or a management problem arises, the village doctor may upload symptoms, ECG recordings, medication information and examination materials through a dedicated telemedicine platform. 3. Standardised guideline training. Village doctors will receive training centred on the AF ABC pathway, covering stroke prevention and anticoagulation, better symptom control, cardiovascular risk-factor management, referral criteria and endpoint identification. 4. Simplified exercise rehabilitation and lifestyle education. Village doctors will deliver enhanced health education in accordance with the study team's 15 core messages for lifestyle-related management

  • OtherUsual Care

    Participants in the control group will receive usual chronic disease management according to the National Basic Public Health Service requirements. Usual care includes routine follow-up, general health education, medication registration, and standard referral procedures provided by local primary care providers. Participants will not receive the structured village-doctor led integrated care program.

06

What researchers measure

Primary outcomes

  1. Primary Outcome of Phase 1: Change in Life's Essential 8 Cardiovascular Health Score

    Mean change in Life's Essential 8 cardiovascular health score from baseline to 12 months. The score includes diet, physical activity, nicotine exposure, sleep health, body mass index, non-HDL cholesterol, blood glucose, and blood pressure.

    Time frame: Baseline to 12 months

  2. Primary Outcome of Phase 2: Composite Cardiovascular Outcome

    Composite cardiovascular endpoint, including cardiovascular death, ischemic or hemorrhagic stroke, hospitalization for worsening heart failure or acute coronary syndrome, and emergency visits due to atrial fibrillation.

    Time frame: Baseline to 36 months

  3. Primary Outcome of Phase 3: New-incident heart-failure diagnosis

    (1) HFrEF - symptomatic cardiac dysfunction with LVEF \< 50%; (2) HFpEF - symptoms of HF with LVEF ≥ 50% and echocardiographic evidence of structural or functional cardiac abnormalities; or (3) hospitalisation with heart failure as a primary cause.

    Time frame: Baseline to 48 months

  4. Primary Outcome of Extension Study: Composite cardiovascular outcome

    Composite cardiovascular endpoint, including cardiovascular death, ischemic or hemorrhagic stroke, hospitalization for worsening heart failure or acute coronary syndrome, and emergency visits due to atrial fibrillation.

    Time frame: Baseline to 84 months

Secondary outcomes

  1. Cardiovascular Death

    Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin. Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular death

    Time frame: 12 months after baseline

  2. Cardiovascular Hospitalization

    Hospitalization due to cardiovascular or neurological diseases at township-level or higher hospitals, including heart failure, cardiac arrhythmia, acute coronary syndrome, hypertensive emergency or urgency, ischemic or hemorrhagic stroke, and transient ischemic attack.

    Time frame: 12 months after baseline

  3. Emergency Visit for Cardiovascular Events

    Incidence of emergency visits for cardiovascular events, including exacerbation of heart failure or acute coronary syndrome.

    Time frame: 12 months after baseline

  4. ischemic or hemorrhagic Stroke

    All strokes: ischemic or hemorrhagic Stroke

    Time frame: 12 months after baseline

  5. The proportion of patients who met all the three criteria for the ABC pathway of integrated AF care

    The 'A' criterion referred to stroke prevention or anticoagulation. 'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) \>65%. Patients who were not properly treated with OACs are considered as 'A non-compliant'. The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control. Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant'). On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled. The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities. 'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated. Otherwise, patients were considered as 'C non-compliant'

    Time frame: 12 month after baseline

  6. Cardiovascular Death

    Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin. Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular deathTime

    Time frame: 36 months after baseline

  7. Ischemic or hemorrhagic Stroke

    All strokes: ischemic or hemorrhagic Stroke

    Time frame: 36 months after baseline

  8. Worsening of heart failure or acute coronary syndrome

    A worsening of heart failure or acute coronary syndrome was defined as the need to be hospitalized or have an emergency visit in conjunction with these conditions

    Time frame: 36 months after baseline

  9. Emergency visit due to AF

    Emergency visit due to AF

    Time frame: 36 months after baseline

  10. All-cause mortality

    all-cause death

    Time frame: 36 months after baseline

  11. The proportion of patients who met all the three criteria for the ABC pathway

    The 'A' criterion referred to stroke prevention or anticoagulation. 'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) \>65%. Patients who were not properly treated with OACs are considered as 'A non-compliant'. The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control. Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant'). On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled. The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities. 'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated. Otherwise, patients were considered as 'C non-compliant'

    Time frame: 36 month after baseline

  12. Cardiovascular Death

    Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin. Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular deathTime

    Time frame: 48 months after baseline

  13. Ischemic or hemorrhagic Stroke

    All strokes: ischemic or hemorrhagic Stroke

    Time frame: 48 months after baseline

  14. Worsening of heart failure or acute coronary syndrome

    A worsening of heart failure or acute coronary syndrome was defined as the need to be hospitalized or have an emergency visit in conjunction with these conditions

    Time frame: 48 months after baseline

  15. Emergency visit due to AF

    Emergency visit due to AF

    Time frame: 48 months after baseline

  16. All-cause mortality

    all-cause death

    Time frame: 48 months after baseline

  17. The proportion of patients who met all the three criteria for the ABC pathway

    The 'A' criterion referred to stroke prevention or anticoagulation. 'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) \>65%. Patients who were not properly treated with OACs are considered as 'A non-compliant'. The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control. Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant'). On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled. The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities. 'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated. Otherwise, patients were considered as 'C non-compliant'

    Time frame: 48 month after baseline

  18. Cardiovascular Death

    Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin. Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular deathTime

    Time frame: 84 months after baseline

  19. Ischemic or hemorrhagic Stroke

    All strokes: ischemic or hemorrhagic Stroke

    Time frame: 84 months after baseline

  20. Worsening of heart failure or acute coronary syndrome

    A worsening of heart failure or acute coronary syndrome was defined as the need to be hospitalized or have an emergency visit in conjunction with these conditions

    Time frame: 84 months after baseline

  21. Emergency visit due to AF

    Emergency visit due to AF

    Time frame: 84 months after baseline

  22. All-cause mortality

    all-cause death

    Time frame: 84 months after baseline

  23. The proportion of patients who met all the three criteria for the ABC pathway

    The 'A' criterion referred to stroke prevention or anticoagulation. 'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) \>65%. Patients who were not properly treated with OACs are considered as 'A non-compliant'. The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control. Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant'). On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled. The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities. 'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated. Otherwise, patients were considered as 'C non-compliant'

    Time frame: 84 month after baseline

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Li M, Chen Y, Chu M, Zhang S, Yang S, Lip GYH, Chen M. Village Doctor-Led Telemedicine for Rural Patients Aged 75 Years and Older With AF: A Prespecified Secondary Analysis of the MIRACLE-AF Trial. JAMA Netw Open. 2026 Mar 2;9(3):e261385. doi: 10.1001/jamanetworkopen.2026.1385. PubMed 41817526 ↗
  • Chu M, Zhang S, Gong J, Yang S, Yang G, Sun X, Wu D, Xia Y, Jiao J, Peng X, Peng Z, Hong L, Wang Z, Li M, Lip GYH, Chen M; MIRACLE-AF Investigators. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med. 2025 Apr;31(4):1276-1285. doi: 10.1038/s41591-025-03511-2. Epub 2025 Feb 21. PubMed 39984634 ↗
  • Li M, Chu M, Shen Y, Zhang S, Yin X, Yang S, Lip GYH, Chen M; MIRACLE-AF Trial Investigators. A Novel Model of Integrated Care of Older Patients With Atrial Fibrillation in Rural China. JACC Asia. 2024 Jul 30;4(10):764-773. doi: 10.1016/j.jacasi.2024.07.006. eCollection 2024 Oct. PubMed 39553909 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2033, 89 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 89 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Aug 2026 → Jul 2026, primary completion Jul 2030 → Dec 2033 and completion Jul 2030 → Dec 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 25, 2026
StartActual
Jul 26, 2026was Aug 2026
Primary completionEst.
Dec 30, 2033was Jul 2030
CompletionEst.
Dec 30, 2033was Jul 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Jul 26, 2026 (actual)
Oct 7, 2026
Primary completion
Jul 1, 2030→Dec 30, 2033
Oct 7, 2026
Study completion
Jul 1, 2030→Dec 30, 2033
Oct 7, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • ChangedBefore A definite history of heart failure, or confirmed cardiac dysfunction or heart failure based on echocardiography and/or NT-proBNP screening. Diagnostic criteria include typical heart failure symptoms or signs with reduced left ventricular ejection fraction (HFrEF, LVEF <40%), mildly reduced left ventricular ejection fraction (HFmrEF, LVEF 40-49%), or preserved left ventricular ejection fraction with elevated NT-proBNP and structural heart disease evidence (HFpEF, LVEF ≥50%, with at least one of the following: LAVI >40 mL/m², E/e' ≥15, or TRV >2.8 m/s).Now A documented history of HF, or newly diagnosed HF according to the 2026 ESC Guidelines for the management of heart failure. HF will require current or prior typical symptoms and/or signs attributable to a structural and/or functional cardiac abnormality. Participants with LVEF <50% will be classified as having heart failure with reduced ejection fraction (HFrEF). In participants with LVEF ≥50%, heart failure with preserved ejection fraction (HFpEF) will require objective evidence of cardiac structural and/or functional abnormalities consistent with left ventricular diastolic dysfunction or elevated filling pressures, supported by elevated natriuretic peptide levels. In participants with AF, supportive echocardiographic abnormalities will include left atrial volume index (LAVI) >40 mL/m², E/e' >15, pulmonary artery systolic pressure >35 mmHg, or tricuspid regurgitation velocity >2.8 m/s.
Oct 7, 2026
Primary outcomes
2 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedPrimary Outcome of Phase 1: Change in Life's Essential 8 Cardiovascular Health ScoreTime frame: Baseline to 12 months
  • EditedPrimary Outcome of Phase 2: Composite Cardiovascular OutcomeTime frame: Baseline to 36 months
  • AddedPrimary Outcome of Phase 3: New-incident heart-failure diagnosisTime frame: Baseline to 48 months
  • AddedPrimary Outcome of Extension Study: Composite cardiovascular outcomeTime frame: Baseline to 84 months
  • RemovedIncidence of Asymptomatic Left Ventricular Dysfunction With or Without Heart FailureTime frame: Baseline to 48 months
Oct 7, 2026
Secondary outcomes
6 added
What changed in the outcomes
  • AddedCardiovascular DeathTime frame: 84 months after baseline
  • AddedIschemic or hemorrhagic StrokeTime frame: 84 months after baseline
  • AddedWorsening of heart failure or acute coronary syndromeTime frame: 84 months after baseline
  • AddedEmergency visit due to AFTime frame: 84 months after baseline
  • AddedAll-cause mortalityTime frame: 84 months after baseline
  • AddedThe proportion of patients who met all the three criteria for the ABC pathwayTime frame: 84 month after baseline
Oct 7, 2026
Title
Novel Model of Integrated Care of Older Patients With Atrial Fibrillation to Prevent Heart Failure in Rural China→A Village Doctor-led Telehealth Supported Trial of Heart Failure Prevention in AF Patients: MIRACLE-AF 2 (Heart Failure Prevention)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Aug 1, 2026→Jul 26, 2026 (now actual)
    Primary completion Jul 1, 2030→Dec 30, 2033
    Study completion Jul 1, 2030→Dec 30, 2033
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • ChangedBefore A definite history of heart failure, or confirmed cardiac dysfunction or heart failure based on echocardiography and/or NT-proBNP screening. Diagnostic criteria include typical heart failure symptoms or signs with reduced left ventricular ejection fraction (HFrEF, LVEF <40%), mildly reduced left ventricular ejection fraction (HFmrEF, LVEF 40-49%), or preserved left ventricular ejection fraction with elevated NT-proBNP and structural heart disease evidence (HFpEF, LVEF ≥50%, with at least one of the following: LAVI >40 mL/m², E/e' ≥15, or TRV >2.8 m/s).Now A documented history of HF, or newly diagnosed HF according to the 2026 ESC Guidelines for the management of heart failure. HF will require current or prior typical symptoms and/or signs attributable to a structural and/or functional cardiac abnormality. Participants with LVEF <50% will be classified as having heart failure with reduced ejection fraction (HFrEF). In participants with LVEF ≥50%, heart failure with preserved ejection fraction (HFpEF) will require objective evidence of cardiac structural and/or functional abnormalities consistent with left ventricular diastolic dysfunction or elevated filling pressures, supported by elevated natriuretic peptide levels. In participants with AF, supportive echocardiographic abnormalities will include left atrial volume index (LAVI) >40 mL/m², E/e' >15, pulmonary artery systolic pressure >35 mmHg, or tricuspid regurgitation velocity >2.8 m/s.
    Primary outcomes 2 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedPrimary Outcome of Phase 1: Change in Life's Essential 8 Cardiovascular Health ScoreTime frame: Baseline to 12 months
    • EditedPrimary Outcome of Phase 2: Composite Cardiovascular OutcomeTime frame: Baseline to 36 months
    • AddedPrimary Outcome of Phase 3: New-incident heart-failure diagnosisTime frame: Baseline to 48 months
    • AddedPrimary Outcome of Extension Study: Composite cardiovascular outcomeTime frame: Baseline to 84 months
    • RemovedIncidence of Asymptomatic Left Ventricular Dysfunction With or Without Heart FailureTime frame: Baseline to 48 months
    Secondary outcomes 6 added
    What changed in the outcomes
    • AddedCardiovascular DeathTime frame: 84 months after baseline
    • AddedIschemic or hemorrhagic StrokeTime frame: 84 months after baseline
    • AddedWorsening of heart failure or acute coronary syndromeTime frame: 84 months after baseline
    • AddedEmergency visit due to AFTime frame: 84 months after baseline
    • AddedAll-cause mortalityTime frame: 84 months after baseline
    • AddedThe proportion of patients who met all the three criteria for the ABC pathwayTime frame: 84 month after baseline
    Title Novel Model of Integrated Care of Older Patients With Atrial Fibrillation to Prevent Heart Failure in Rural China→A Village Doctor-led Telehealth Supported Trial of Heart Failure Prevention in AF Patients: MIRACLE-AF 2 (Heart Failure Prevention)
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07492498
Lead sponsor
Jiangsu Taizhou People's Hospital
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Jul 26, 2026
Primary completion
Dec 30, 2033 (estimated)
Completion
Dec 30, 2033 (estimated)
Last update
Oct 7, 2026

Study contacts

Ming Chu
Contact
chuming@njmu.edu.cn
13814010410

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion